ERBB2 Mutation

CI-VAR-00002687Explore in graph →CIViC 666

Curated evidence

Evidence by cancer (6 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–6 of 6 evidence items across 4 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma1
ERBB2 Mutation	Platinum Compound	Predictive	C	Supports Sensitivity Response	3	accepted	EID1694 In patients with muscle-invasive bladder chancer, a cohort of complete responders to platinum chemotherapy (n=38) and non-responders to platinum chemotherapy (n=33) were evaluated for 178 cancer-assoc… (full text at CIViC) PMID 25636205 · Groenendijk et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma3
ERBB2 Mutation	Trastuzumab Deruxtecan	Predictive	A	Supports Sensitivity Response	4	accepted	EID11731 In a phase 2 trial, 152 previously-treated metastatic NSCLC patients harboring mutations in ERBB2 (HER2) were treated with 2 different doses of the HER2 ADC trastuzumab deruxtecan (5.4 mg/kg and 6.4 m… (full text at CIViC)

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Breast Neoplasm1
ERBB2 Mutation	Neratinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID5338 16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Fiv… (full text at CIViC) PMID 28679771 · Ma et al., 2017 · Open in CIViC	civic

Malignant Colorectal Neoplasm1
ERBB2 Mutation OR ERBB3 Mutation	Pertuzumab + TrastuzumabCombination	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID11669 In this clinical study of 38 patients with colorectal cancer (CRC), 10 had CRC with ERBB2/ERBB3 mutation, and were treated with a combination of Pertuzumab and Trastuzumab. A DC of 10% and OR of 0% we… (full text at CIViC) PMID 36315917 · Gupta et al., 2022 · Open in CIViC	civic